Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EMMALIND APONTE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1699985002
CMS profile
895385
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$783.98

11 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $736.96 9
Education $47.02 2

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EMMALIND APONTE

NPI 1699985002 · CMS profile ID 895385

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1699985002?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EMMALIND APONTE, NPI 1699985002, CMS profile ID 895385. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1699985002?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). EMMALIND APONTE, NPI 1699985002, CMS profile ID 895385. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1699985002?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
EMMALIND APONTE, NPI 1699985002, CMS profile ID 895385, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1699985002?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

11 matching records · $783.98 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 11 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–11 of 11.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Myriad Genetic Laboratories, Inc. $117.4412/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152526702 CMS
Regeneron Healthcare Solutions, Inc. $17.0211/15/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114000589 CMS
AstraZeneca Pharmaceuticals LP $124.9910/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104783152 CMS
Genmab U.S., Inc. $124.9909/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126826372 CMS
Bayer Healthcare Pharmaceuticals Inc. $124.9907/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086115280 CMS
Alexion Pharmaceuticals, Inc. $30.0007/02/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1094015266 CMS
Myriad Genetic Laboratories, Inc. $18.8905/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152526700 CMS
E.R. Squibb & Sons, L.L.C. $21.0505/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101272273 CMS
Takeda Pharmaceuticals U.S.A., Inc. $99.7104/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144952881 CMS
E.R. Squibb & Sons, L.L.C. $19.2502/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101272253 CMS
GENZYME CORPORATION $85.6501/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139759930 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,364.35 107
PY2020 $526.62 12
PY2021 $133.09 3
PY2022 $360.12 5
PY2023 $966.65 21
PY2024 $783.98 11
PY2025 $663.11 15

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $813,810.23 86
PY2024 Principal investigator $353,805.35 318
PY2023 Principal investigator $781,091.71 185
PY2022 Principal investigator $668,992.46 76
PY2021 Principal investigator $746,317.94 121
PY2020 Principal investigator $559,338.29 124
PY2019 Recipient $1,341.00 1
PY2019 Principal investigator $441,514.52 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

124 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Seagen Inc. $3,854.17 12/28/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903589
Principal investigator 1 Seagen Inc. $3,854.17 12/28/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903611
Principal investigator 1 GlaxoSmithKline, LLC. $3,750.00 12/22/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-022, AN AN No dispute reported 06/30/2026 734912933
Principal investigator 1 Seagen Inc. $3,854.17 12/17/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903587
Principal investigator 1 Seagen Inc. $3,854.17 12/17/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903609
Principal investigator 1 Seagen Inc. $2,150.00 12/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446653
Principal investigator 1 Seagen Inc. $30.00 12/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446655
Principal investigator 1 Seagen Inc. $2,150.00 12/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446665
Principal investigator 1 Seagen Inc. $3,854.17 12/08/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903585
Principal investigator 1 Seagen Inc. $3,854.17 12/08/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903607
Principal investigator 1 Seagen Inc. $3,854.17 11/18/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903583
Principal investigator 1 Seagen Inc. $3,854.17 11/18/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903601
Principal investigator 1 Seagen Inc. $3,854.17 11/18/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903603
Principal investigator 1 Seagen Inc. $3,854.17 11/18/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903605
Principal investigator 1 Merck Sharp & Dohme Corporation $19,541.97 11/16/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO MEDICAL CENTER
An Open-label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer TNBC KEYLYNK 009 No dispute reported 06/30/2026 740702253
Principal investigator 1 Merck Sharp & Dohme Corporation $579.36 11/16/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO MEDICAL CENTER
An Open-label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer TNBC KEYLYNK 009 No dispute reported 06/30/2026 740702329
Principal investigator 1 Seagen Inc. $2,150.00 11/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446645
Principal investigator 1 Seagen Inc. $30.00 11/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446649
Principal investigator 1 Seagen Inc. $3,430.00 11/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446651
Principal investigator 1 Seagen Inc. $2,150.00 11/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446657
Principal investigator 1 Seagen Inc. $30.00 11/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446661
Principal investigator 1 Seagen Inc. $2,150.00 11/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446663
Principal investigator 1 Seagen Inc. $3,854.17 11/04/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903581
Principal investigator 1 Seagen Inc. $3,854.17 11/04/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903599
Principal investigator 1 Seagen Inc. $3,854.17 11/03/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903579
Principal investigator 1 Seagen Inc. $3,854.17 11/03/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903597
Principal investigator 1 PFIZER INC. $1,250.00 10/17/2020 Non-covered Recipient Entity
US Oncology Research LLC
PHASE 2 STUDY IN PATIENTS WITH NEOADJUVANT BREAST CANCER No dispute reported 06/30/2026 742923513
Principal investigator 1 Seagen Inc. $956.00 10/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446637
Principal investigator 1 Seagen Inc. $3,230.00 10/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446639
Principal investigator 1 Seagen Inc. $1,950.00 10/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446643
Principal investigator 1 Seagen Inc. $3,854.17 10/12/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903577
Principal investigator 1 Seagen Inc. $3,854.17 10/12/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903591
Principal investigator 1 Seagen Inc. $3,854.17 10/12/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903593
Principal investigator 1 Seagen Inc. $3,854.17 10/12/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903595
Principal investigator 1 Seagen Inc. $3,854.17 09/22/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903559
Principal investigator 1 Seagen Inc. $3,854.17 09/22/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903575
Principal investigator 1 Merck Sharp & Dohme Corporation $9,500.00 09/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO MEDICAL CENTER
An Open-label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer TNBC KEYLYNK 009 No dispute reported 06/30/2026 740760871
Principal investigator 1 Seagen Inc. $2,150.00 09/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446591
Principal investigator 1 Seagen Inc. $30.00 09/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446593
Principal investigator 1 Seagen Inc. $2,145.00 09/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446595
Principal investigator 1 Seagen Inc. $450.00 09/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446597
Principal investigator 1 Seagen Inc. $450.00 09/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446603
Principal investigator 1 Seagen Inc. $3,854.17 09/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903557
Principal investigator 1 Seagen Inc. $3,854.17 09/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903573
Principal investigator 1 Seagen Inc. $3,854.17 09/02/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903555
Principal investigator 1 Seagen Inc. $3,854.17 09/02/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903571
Principal investigator 1 Seagen Inc. $3,854.17 08/31/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903553
Principal investigator 1 Seagen Inc. $3,854.17 08/31/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903569
Principal investigator 1 Seagen Inc. $30.00 08/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446583
Principal investigator 1 Seagen Inc. $2,140.00 08/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446585
Principal investigator 1 Seagen Inc. $2,150.00 08/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446587
Principal investigator 1 Seagen Inc. $450.00 08/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446589
Principal investigator 1 Seagen Inc. $30.00 08/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446601
Principal investigator 1 Seagen Inc. $3,854.17 08/10/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903551
Principal investigator 1 Seagen Inc. $3,854.17 08/10/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903567
Principal investigator 1 Seagen Inc. $3,854.17 08/03/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903549
Principal investigator 1 Seagen Inc. $3,854.17 08/03/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903565
Principal investigator 1 Seagen Inc. $3,854.17 07/20/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903547
Principal investigator 1 Seagen Inc. $3,854.17 07/20/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903563
Principal investigator 1 Seagen Inc. $30.00 07/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446571
Principal investigator 1 Seagen Inc. $450.00 07/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446573
Principal investigator 1 Seagen Inc. $3,230.00 07/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446575
Principal investigator 1 Seagen Inc. $956.00 07/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446577
Principal investigator 1 Seagen Inc. $1,950.00 07/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446579
Principal investigator 1 Seagen Inc. $3,636.00 07/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446581
Principal investigator 1 Seagen Inc. $450.00 07/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446599
Principal investigator 1 Seagen Inc. $3,854.17 07/01/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903545
Principal investigator 1 Seagen Inc. $3,854.17 07/01/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903561
Principal investigator 1 Seagen Inc. $3,854.17 06/30/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903525
Principal investigator 1 Seagen Inc. $3,854.17 06/30/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903539
Principal investigator 1 Genentech, Inc. $400.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY SOUTHWEST FORT WORTH
GAZYVA GA101 PLUS BENDA CLL No dispute reported 06/30/2026 743162403
Principal investigator 1 Seagen Inc. $2,000.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446553
Principal investigator 1 Seagen Inc. $2,851.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446557
Principal investigator 1 Seagen Inc. $2,610.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446559
Principal investigator 1 Seagen Inc. $2,145.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446561
Principal investigator 1 Seagen Inc. $450.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446563
Principal investigator 1 Seagen Inc. $3,854.17 06/08/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903523
Principal investigator 1 Seagen Inc. $3,854.17 06/08/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903533
Principal investigator 1 Seagen Inc. $3,854.17 06/08/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903535
Principal investigator 1 Seagen Inc. $3,854.17 06/08/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903537
Principal investigator 1 Seagen Inc. $3,854.17 05/20/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903521
Principal investigator 1 Seagen Inc. $3,854.17 05/20/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903531
Principal investigator 1 Seagen Inc. $2,000.00 05/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446533
Principal investigator 1 Seagen Inc. $500.00 05/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446535
Principal investigator 1 Seagen Inc. $2,140.00 05/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446537
Principal investigator 1 Seagen Inc. $4,263.00 05/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446539
Principal investigator 1 Seagen Inc. $2,865.00 05/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446541
Principal investigator 1 Seagen Inc. $450.00 05/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446543
Principal investigator 1 Seagen Inc. $85.00 05/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446545
Principal investigator 1 Seagen Inc. $1,445.00 05/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446547
Principal investigator 1 Seagen Inc. $188.00 05/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446549
Principal investigator 1 Seagen Inc. $40.00 05/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446551
Principal investigator 1 Seagen Inc. $1,445.00 05/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446565
Principal investigator 1 Seagen Inc. $1,445.00 05/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446567
Principal investigator 1 Seagen Inc. $3,854.17 05/13/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903519
Principal investigator 1 Seagen Inc. $3,854.17 05/13/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903529
Principal investigator 1 Seagen Inc. $3,854.17 05/11/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903517
Principal investigator 1 Seagen Inc. $3,854.17 05/11/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903527
Principal investigator 1 Seagen Inc. $3,854.17 04/30/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903515
Principal investigator 1 Seagen Inc. $3,854.17 04/30/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903543
Principal investigator 1 Eli Lilly and Company $104,211.00 04/28/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 728752363
Principal investigator 1 Merck Sharp & Dohme Corporation $225.40 04/27/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO MEDICAL CENTER
An Open-label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer TNBC KEYLYNK 009 No dispute reported 06/30/2026 740702219
Principal investigator 1 Seagen Inc. $3,854.17 04/27/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903513
Principal investigator 1 Seagen Inc. $3,854.17 04/27/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 753903541
Principal investigator 1 Amgen Inc. $34,250.00 04/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P A
Prospective Observational Study of Onpro vs SOC. No dispute reported 06/30/2026 731642639
Principal investigator 1 Seagen Inc. $2,610.00 04/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446525
Principal investigator 1 Seagen Inc. $3,636.00 04/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446527
Principal investigator 1 Seagen Inc. $956.00 04/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446531
Principal investigator 1 Genentech, Inc. $3,828.50 03/23/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
GAZYVA GA101 PLUS BENDA CLL No dispute reported 06/30/2026 743193312
Principal investigator 1 Seagen Inc. $40.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446483
Principal investigator 1 Seagen Inc. $2,851.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446487
Principal investigator 1 Seagen Inc. $1,445.00 02/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446285
Principal investigator 1 Seagen Inc. $4,263.00 02/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446287
Principal investigator 1 Seagen Inc. $85.00 02/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446289
Principal investigator 1 Seagen Inc. $2,865.00 02/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446479
Principal investigator 1 Seagen Inc. $500.00 02/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446481
Principal investigator 1 Seagen Inc. $1,445.00 02/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446489
Principal investigator 1 Seagen Inc. $1,445.00 02/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446491
Principal investigator 1 Eli Lilly and Company $333.05 02/10/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 728745655
Principal investigator 1 Merck Sharp & Dohme Corporation $980.40 01/22/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO MEDICAL CENTER
An Open-label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer TNBC KEYLYNK 009 No dispute reported 06/30/2026 740760873
Principal investigator 1 Eli Lilly and Company $90,637.00 01/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 728745659
Principal investigator 1 Seagen Inc. $6,800.00 01/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY - SAN ANTONIO MEDICAL CENTER
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 733446281
Principal investigator 1 Eli Lilly and Company $50.06 01/13/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY PA
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 728750421
Principal investigator 1 Merck Sharp & Dohme Corporation $97.05 01/06/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY SAN ANTONIO MEDICAL CENTER
An Open-label, Randomized, Phase 2,3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants With Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer TNBC KEYLYNK 009 No dispute reported 06/30/2026 740760867